To enhance access to proton therapy in India
Royal Philips and IBA have signed an exclusive agreement to enhance access to proton therapy in India. The alliance aims combines Philips’ expertise in clinical informatics and innovative imaging techniques for therapy planning and guidance and IBA’s strengths in proton therapy. This agreement builds upon the collaboration between Philips India and IBA, which started in 2013, to build the Apollo Proton Therapy Center.
Sameer Garde, President, Philips Healthcare said, “We are very pleased to announce that Philips India and IBA are introducing the best-in-class proton beam therapy for cancer patients in India. We are confident that the future launch of the first proton therapy center in Apollo Hospitals, Chennai, will mark the beginning of a new phase in cancer treatment in the country and also the subcontinent”.
Olivier Legrain, CEO, IBA, added, “We are privileged that Philips India is supporting us in bringing cutting edge proton beam therapy to India. We are certain that this initiative will be a significant step in improving the quality of cancer treatment in the country.”
The exclusive Philips-IBA agreement for India follows the framework agreement that Philips and IBA signed in September of last year. The framework agreement comprises research and development, marketing and sales of imaging and therapy solutions in oncology. The collaboration also enables both organisations to mutually leverage technologies and solutions: IBA benefits from Philips diagnostic imaging products offered to oncology care centres, while Philips will leverage IBA proton therapy solutions within its offering for customers in select markets around the world. As part of the framework agreement, Philips and IBA have already signed multiple country-specific collaboration agreements, each optimised for the local market needs.
EH News Bureau